# Emmanuel H Demont

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1104337/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 38 papers | 1,855 citations | 257357 24 h-index | 315616 38 g-index |
| 40 all docs | 40 docs citations | 40 times ranked | 1837 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Multigram Synthesis of Tetrasubstituted Dihydrobenzofuran GSK973 Enabled by High-Throughput Experimentation and a Claisen Rearrangement in Flow. Organic Process Research and Development, 2022, 26, 365-379. | 1.3 | 2 |
| 2 | Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 3249-3281. | 2.9 | 19 |
| 3 | Discovery of a Highly Selective BET BD2 Inhibitor from a DNA-Encoded Library Technology Screening Hit. Journal of Medicinal Chemistry, 2021, 64, 10806-10833. | 2.9 | 31 |
| 4 | Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 10711-10741. | 2.9 | 17 |
| 5 | Identification of a Series of N-Methylpyridine-2-carboxamides as Potent and Selective Inhibitors of the Second Bromodomain (BD2) of the Bromo and Extra Terminal Domain (BET) Proteins. Journal of Medicinal Chemistry, 2021, 64, 10742-10771. | 2.9 | 14 |
| 6 | Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 10772-10805. | 2.9 | 17 |
| 7 | Optimization of Naphthyridones into Selective TATA-Binding Protein Associated Factor 1 (TAF1) Bromodomain Inhibitors. ACS Medicinal Chemistry Letters, 2021, 12, 1308-1317. | 1.3 | 4 |
| 8 | Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression. Journal of Medicinal Chemistry, 2021, 64, 12200-12227. | 2.9 | 26 |
| 9 | Design and Synthesis of a Highly Selective and In Vivo-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of Proteins. Journal of Medicinal Chemistry, 2020, 63, 9070-9092. | 2.9 | 40 |
| 10 | GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins. Journal of Medicinal Chemistry, 2020, 63, 9045-9069. | 2.9 | 59 |
| 11 | The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor. Journal of Medicinal Chemistry, 2020, 63, 9093-9126. | 2.9 | 41 |
| 12 | Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype. Journal of Medicinal Chemistry, 2020, 63, 9020-9044. | 2.9 | 38 |
| 13 | Domain-selective targeting of BET proteins in cancer and immunological diseases. Current Opinion in Chemical Biology, 2020, 57, 184-193. | 2.8 | 43 |
| 14 | Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science, 2020, 368, 387-394. | 6.0 | 274 |
| 15 | GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) Family. ACS Medicinal Chemistry Letters, 2020, 11, 1581-1587. | 1.3 | 25 |
| 16 | Optimization of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding Mode. Journal of Medicinal Chemistry, 2020, 63, 5212-5241. | 2.9 | 14 |
| 17 | A Qualified Success: Discovery of a New Series of ATAD2 Bromodomain Inhibitors with a Novel Binding Mode Using High-Throughput Screening and Hit Qualification. Journal of Medicinal Chemistry, 2019, 62, 7506-7525. | 2.9 | 19 |
| 18 | Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain. Journal of Medicinal Chemistry, 2018, 61, 4317-4334. | 2.9 | 94 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Aiming to Miss a Moving Target: Bromo and Extra Terminal Domain (BET) Selectivity in Constrained ATAD2 Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 8321-8336. | 2.9 | 17 |
| 20 | A Chemical Probe for the ATAD2 Bromodomain. Angewandte Chemie, 2016, 128, 11554-11558. | 1.6 | 10 |
| 21 | A Chemical Probe for the ATAD2 Bromodomain. Angewandte Chemie - International Edition, 2016, 55, 11382-11386. | 7.2 | 67 |
| 22 | Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P<sub>3</sub>)-Sparing S1P<sub>1</sub> Agonists Active at Low Oral Doses. Journal of Medicinal Chemistry, 2016, 59, 1003-1020. | 2.9 | 10 |
| 23 | Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 6151-6178. | 2.9 | 81 |
| 24 | Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 5649-5673. | 2.9 | 75 |
| 25 | Navigating CYP1A Induction and Arylhydrocarbon Receptor Agonism in Drug Discovery. A Case History with S1P<sub>1</sub> Agonists. Journal of Medicinal Chemistry, 2015, 58, 8236-8256. | 2.9 | 15 |
| 26 | Optimization of Sphingosine-1-phosphate-1 Receptor Agonists: Effects of Acidic, Basic, and Zwitterionic Chemotypes on Pharmacokinetic and Pharmacodynamic Profiles. Journal of Medicinal Chemistry, 2014, 57, 10424-10442. | 2.9 | 19 |
| 27 | The Discovery of I-BET726 (GSK1324726A), a Potent Tetrahydroquinoline ApoA1 Up-Regulator and Selective BET Bromodomain Inhibitor. Journal of Medicinal Chemistry, 2014, 57, 8111-8131. | 2.9 | 159 |
| 28 | Discovery of a Selective S1P<sub>1</sub> Receptor Agonist Efficacious at Low Oral Dose and Devoid of Effects on Heart Rate. ACS Medicinal Chemistry Letters, 2011, 2, 444-449. | 1.3 | 27 |
| 29 | Discovery of a Brain-Penetrant S1P<sub>3</sub>-Sparing Direct Agonist of the S1P<sub>1</sub> and S1P<sub>5</sub> Receptors Efficacious at Low Oral Dose. Journal of Medicinal Chemistry, 2011, 54, 6724-6733. | 2.9 | 31 |
| 30 | BACE-1 hydroxyethylamine inhibitors using novel edge-to-face interaction with Arg-296. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4639-4644. | 1.0 | 12 |
| 31 | Second generation of BACE-1 inhibitors part 3: Towards non hydroxyethylamine transition state mimetics. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3674-3678. | 1.0 | 53 |
| 32 | Second generation of BACE-1 inhibitors part 2: Optimisation of the non-prime side substituent. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3669-3673. | 1.0 | 45 |
| 33 | Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3664-3668. | 1.0 | 46 |
| 34 | BACE-1 inhibitors Part 1: Identification of novel hydroxy ethylamines (HEAs). Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1011-1016. | 1.0 | 45 |
| 35 | BACE-1 inhibitors part 2: Identification of hydroxy ethylamines (HEAs) with reduced peptidic character. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1017-1021. | 1.0 | 55 |
| 36 | BACE-1 inhibitors part 3: Identification of hydroxy ethylamines (HEAs) with nanomolar potency in cells. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1022-1026. | 1.0 | 62 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Second Generation of Hydroxyethylamine BACE-1 Inhibitors: Optimizing Potency and Oral Bioavailability. Journal of Medicinal Chemistry, 2008, 51, 3313-3317. | 2.9 | 62 |
| 38 | Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases ?-cleavage of amyloid precursor protein and amyloid-? production in vivo. Journal of Neurochemistry, 2007, 100, 802-809. | 2.1 | 186 |